Drug Profile

C KAD

Alternative Names: C-KAD; Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution - Livionex

Latest Information Update: 06 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LIVIONEX
Class Anticoagulants; Ethylenediamines; Eye disorder therapies; Small molecules
Mechanism of Action Chelating agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Corneal disorders
Phase I/II Cataracts

Most Recent Events

30 Sep 2025 Phase-III clinical trials in Corneal disorders in USA (Ophthalmic) (Livionex pipeline; September 2025)
17 Apr 2024 Livionex has patent protection for its metal ion modulation technology (Livionex website April 2024)
17 Apr 2024 Efficacy data from a phase I/II trial in Cataracts released by Livionex before April 2024 (Livionex website, April 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com